Organon & Co (OGN)
21.33
+0.39
(+1.86%)
USD |
NYSE |
May 31, 16:00
21.34
0.00 (0.00%)
Pre-Market: 20:00
Organon Cash from Financing (TTM): -317.00M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -317.00M |
December 31, 2023 | -569.00M |
September 30, 2023 | -574.00M |
June 30, 2023 | -573.00M |
March 31, 2023 | -668.00M |
December 31, 2022 | -433.00M |
September 30, 2022 | -182.00M |
Date | Value |
---|---|
June 30, 2022 | -123.00M |
March 31, 2022 | 293.00M |
December 31, 2021 | -977.00M |
September 30, 2021 | -1.823B |
June 30, 2021 | -2.108B |
March 31, 2021 | -2.918B |
December 31, 2020 | -2.175B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-2.918B
Minimum
Mar 2021
293.00M
Maximum
Mar 2022
-939.07M
Average
-573.50M
Median
Cash from Financing (TTM) Benchmarks
Amgen Inc | -2.169B |
Pfizer Inc | 23.91B |
Pacira BioSciences Inc | -31.94M |
Amphastar Pharmaceuticals Inc | 454.06M |
Moderna Inc | -821.00M |